Sanofi (SNY) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SNY Revenue Growth
Revenue Breakdown
SNY's revenue distribution by segment and geography
By Geography
SNY Revenue Analysis (2014–2025)
As of May 6, 2026, Sanofi (SNY) generated trailing twelve-month (TTM) revenue of $46.72 billion, reflecting explosive growth of +59.9% year-over-year. The most recent quarter (Q4 2025) recorded $12.21 billion in revenue, down 7.3% sequentially.
Looking at the longer-term picture, SNY's 5-year compound annual growth rate (CAGR) stands at +4.6%, indicating moderate growth over time. The company achieved its highest annual revenue of $46.72 billion in 2025, representing a new all-time high.
When compared to Healthcare sector peers including NVO (+2.3% YoY), AZN (+9.9% YoY), and NVS (+5.3% YoY), SNY has outperformed the peer group in terms of revenue growth. Compare SNY vs NVO →
SNY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SNYCurrent | $46.7B | +59.9% | +4.6% | 13.6% | |
 NVO | $297.2B | +2.3% | +18.5% | 41.4% | |
 AZN | $58.7B | +9.9% | +17.2% | 23.4% | |
 NVS | $54.8B | +5.3% | +1.9% | 31.2% | |
 GSK | $32.7B | +5.4% | +6.0% | 25.5% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% |
SNY Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $46.72B | +5.5% | $33.79B | 72.3% | $6.34B | 13.6% |
| 2024 | $44.29B | +6.4% | $31.08B | 70.2% | $7.25B | 16.4% |
| 2023 | $41.62B | +2.6% | $28.99B | 69.7% | $6.96B | 16.7% |
| 2022 | $40.56B | +3.5% | $28.68B | 70.7% | $10.16B | 25.1% |
| 2021 | $39.17B | +4.8% | $26.92B | 68.7% | $8.13B | 20.7% |
| 2020 | $37.37B | -0.7% | $25.21B | 67.5% | $14.11B | 37.8% |
| 2019 | $37.63B | +5.5% | $25.65B | 68.2% | $3.05B | 8.1% |
| 2018 | $35.68B | -1.5% | $24.24B | 67.9% | $4.68B | 13.1% |
| 2017 | $36.22B | +4.4% | $24.61B | 67.9% | $5.80B | 16.0% |
| 2016 | $34.70B | -0.5% | $24.00B | 69.2% | $6.53B | 18.8% |
Full SNY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSNY — Frequently Asked Questions
Quick answers to the most common questions about buying SNY stock.
Is SNY's revenue growth accelerating or slowing?
SNY revenue is accelerating at +59.9% year-over-year, exceeding the 5-year CAGR of +4.6%. TTM revenue reached $46.7B. Growth momentum has increased versus prior periods.
What is SNY's long-term revenue growth rate?
Sanofi's 5-year revenue CAGR of +4.6% reflects the sustained expansion pattern. Current YoY growth of +59.9% is above this long-term average.
How is SNY's revenue distributed by segment?
SNY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.